UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9219-9226

2005

Volltextzugriff (PDF)

The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

British journal of haematology, 2023-01, Vol.200 (2), p.e17-e21

2023

Volltextzugriff (PDF)

Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma

Journal of clinical pathology, 2022-01, Vol.75 (1), p.50-57

2022

Volltextzugriff (PDF)

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Internal medicine journal, 2023-04, Vol.53 (4), p.599-609

2023

Volltextzugriff (PDF)

Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed?

Medical journal of Australia, 2006-04, Vol.184 (7), p.365-366

2006

Volltextzugriff (PDF)

Postpartum anti‐D: can we safely reduce the dose?

Medical journal of Australia, 2006-06, Vol.184 (12), p.611-613

2006

Volltextzugriff (PDF)

Serum Free Light Chain Levels in Asymptomatic Myeloma

Blood, 2004-11, Vol.104 (11), p.4880-4880

2004

Volltextzugriff (PDF)

Long-Term Survival in Patients Receiving Conventional Therapy for Newly Diagnosed Multiple Myeloma; Results from United Kingdom Medical Research Council Trials 1980–1997

Blood, 2004-11, Vol.104 (11), p.4921-4921

2004

Volltextzugriff (PDF)

Early Mortality Following Diagnosis of Multiple Myeloma; Analysis of Patients Entered into the UK Medical Research Council Trials 1980–2002

Blood, 2004-11, Vol.104 (11), p.3465-3465

2004

Volltextzugriff (PDF)

Correlation of Serum Free Light Chains and Bone Marrow Plasma Cell Infiltration in Multiple Myeloma

Blood, 2004-11, Vol.104 (11), p.4865-4865

2004

Volltextzugriff (PDF)

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

PloS one, 2024-08, Vol.19 (8), p.e0308812

2024

Volltextzugriff (PDF)

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-08, Vol.375 (8), p.754-766

2016

Volltextzugriff (PDF)

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study

Haematologica (Roma), 2024-07, Vol.109 (7), p.2229

2024

Volltextzugriff (PDF)

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

BMC medical research methodology, 2016-11, Vol.16 (1), p.151-151, Article 151

2016

Volltextzugriff (PDF)

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Blood advances, 2019-07, Vol.3 (13), p.2013-2021

2019

Volltextzugriff (PDF)

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Blood, 2020-11, Vol.136 (Supplement 1), p.30-31

2020

Volltextzugriff (PDF)

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.269-269

2019

Volltextzugriff (PDF)

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1955-1955

2018

Volltextzugriff (PDF)

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

Clinical lymphoma, myeloma and leukemia, 2019-08, Vol.19 (8), p.e415-e424

2019

Volltextzugriff (PDF)

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

American journal of hematology, 2016-09, Vol.91 (9), p.894-899

2016

Volltextzugriff (PDF)

Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma

Value in health, 2011-07, Vol.14 (5), p.672-678

2011

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(13)
Middle Aged
(8)
Multiple Myeloma
(8)
Aged
(7)
Female
(7)
Male
(7)
Adult
(6)
Hematology
(6)
Treatment Outcome
(6)
Aged, 80 And Over
(4)
Disease-Free Survival
(4)
General & Internal Medicine
(4)
Medicine, General & Internal
(4)
Multiple Myeloma - Drug Therapy
(4)
Patients
(4)
Retrospective Studies
(4)
Adolescent
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party

Variation in immunoglobulin use and impact on survival in myeloma

The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed?

Postpartum anti‐D: can we safely reduce the dose?

Serum Free Light Chain Levels in Asymptomatic Myeloma

Long-Term Survival in Patients Receiving Conventional Therapy for Newly Diagnosed Multiple Myeloma; Results from United Kingdom Medical Research Council Trials 1980–1997

Early Mortality Following Diagnosis of Multiple Myeloma; Analysis of Patients Entered into the UK Medical Research Council Trials 1980–2002

Correlation of Serum Free Light Chains and Bone Marrow Plasma Cell Infiltration in Multiple Myeloma

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

PB2122: A PHASE 1/2 MULTI‐CENTER, DOSE‐FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN‐D5, A NOVEL BCL‐2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma

Suchergebnisse filtern